Clinical trials: Rectum Carcinoma
Early Low Rectal Cancer
Short-course Radiotherapy Combined With CAPOX and PD-1 Antibody Versus Long-course Chemoradiotherapy Combined With CAPOX for Early Low-lying Rectal Cancer
TORCH-E2 is a prospective, multicentre, randomized phase II trial. 134 low-lying early (T1-3b/N0-1M0, distance from anal verge ≤5cm) patients will be recruited and assigned to Group 1 and Group 2 (1:1).
- Trial name
- TORCH-E2 (NCT06462053)
- Testing
- Short-course radiotherapy, PD-1 antibody (Toripalimab), Long-course radiotherapy
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Fudan University
Radiation-induced Intestinal Injury
Prediction of the Chronicization of Radiation-induced Acute Intestinal Injury Based on the Expression Level of lncRNA
Our team has constructed a prediction model based on the expression level of lncRNA (lncRNA-UCID、NEAT1、ciRS-7) to predict the chronicization of radiation-induced acute intestinal injury (RAII) and verified the predictive efficacy…
- Trial name
- PCRAII (NCT05749497)
- Testing
- NCRT+TME
- Volunteers
- 200 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Colorectal Cancer, Metastatic Cancer
Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, irinotecan, fluorouracil and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00513266
- Testing
- bevacizumab, cetuximab, fluorouracil
- Where
- 4 sites in Switzerland
- Volunteers
- 35 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Minimal Residual Disease, KRAS G12D
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides])…
- Conditions
- Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D
- Trial name
- AMPLIFY-201 (NCT04853017)
- Testing
- ELI-002 2P
- Where
- 10 sites in United States
- Volunteers
- 25 people
- Sponsor
- Elicio Therapeutics
Rectal Cancer Stage I
Preoperative Chemoradiotherapy and Transanal Endoscopic Microsurgery Versus Ttransanal Endoscopic Microsurgery in T1 N0, M0 Rectal Cancer (TAUTEM-T1 Study)
Introduction: The standard treatment for rectal adenocarcinoma is total mesorectal excision (TME), a technique involving resection of the rectum, with or without a temporary or permanent stoma.
- Trial name
- TAUTEM-T1 (NCT06450574)
- Testing
- Capecitabine (Xeloda), 50.4 Gy, Transanal Endoscopic Microsurgery (TEM)
- Volunteers
- 106 people
- Sponsor
- Corporacion Parc Tauli
Rectal Neoplasms
The Safety and Efficiency of Stent-based Diverting Technique Versus Ileostomy in Rectal Cancer Patients
The goal of this clinical trial is to evaluate the safety and efficiency of stent-based tiverting technique (SDT) versus ileostomy in rectal cancer patients.
- Trial name
- NCT06204497
- Testing
- Stent-based Diverting Technique
- Where
- 20 sites in China
- Volunteers
- 570 people
- Sponsor
- Sir Run Run Shaw Hospital
Pancreatic Cancer, Colo-rectal Cancer
Prehabilitation in High-risk Oncologic Surgery
The goal of this clinical study is to learn whether a prehabilitation program can improve recovery after major abdominal surgery in adults with cancer who are receiving treatment before surgery.
- Conditions
- Pancreatic Cancer, Colo-rectal Cancer, Gastric Cancer, Esophageal Cancer
- Trial name
- NCT07638410
- Testing
- Multidisciplinary Prehabilitation Program
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Fox Chase Cancer Center
Advanced Solid Tumor, Non-Small Cell Lung Cancer
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or…
- Conditions
- Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07629960
- Testing
- BLU-924
- Where
- 16 sites in United States, Spain
- Volunteers
- 265 people
- Sponsor
- Blueprint Medicines Corporation
Gastric Cancer, Colo-rectal Cancer
Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer
Immunotherapy acquired resistance was observed in clinical practice. The investigators intended to add anlotinib to PD-1 inhibitors, hoping reverse the resistance.
- Trial name
- NCT04777162
- Testing
- Tislelizumab, Anlotinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University
Rectal Cancer
Robotic Versus Laparoscopic Approach for Rectal Cancer Surgery
Colorectal cancer is a common malignancy in Viet Nam. Laparoscopic surgery becomes a standard treatment in many centers. Today, robotic surgery is a new option for treating colorectal cancer with some advantages such as magnified…
- Trial name
- NCT03931980
- Testing
- Robotic-assisted rectal cancer resection and Laparoscopic rectal cancer resection
- Where
- Vietnam
- Volunteers
- 100 people
- Sponsor
- Binh Dan Hospital
Locally Advanced Rectal Carcinoma, Circulating Tumor DNA
Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer
Rectal cancer still remains one of the most popular tumors, however, distance metastasis still remains as high as 30% and the long-term survival outcomes are still unsatisfying.
- Trial name
- CINTS-R (NCT05601505)
- Testing
- circulating tumor DNA
- Where
- China
- Volunteers
- 470 people
- Sponsor
- Peking Union Medical College Hospital
Rectal Cancer
A Study on the Accurate Evaluation of Pseudoprogression of Rectal Cancer Immunotherapy Based on Multitemporal and Multiparameter MRI
This project aims to use multi-temporal, multi-parameter MRI features, blood biomarkers, and clinical indicators to accurately assess pseudoprogression following immunotherapy in rectal cancer.
- Trial name
- NCT07381322
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Peiyi Xie
Locally Advanced Rectal Cancer
SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer
This study will evaluate the efficacy and safety of SHR-1701 combined with radiotherapy and chemotherapy as perioperative treatment for locally advanced rectal cancer.
- Trial name
- NCT05300269
- Testing
- SHR-1701；Capecitabine；Oxaliplatin
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Colorectal Cancer
Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as ursodiol, oxaliplatin, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00873275
- Testing
- bevacizumab, FOLFOX regimen, fluorouracil
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- City of Hope Medical Center
Breast Cancer (Triple Negative Breast Cancer (TNBC)), Renal Cell Carcinoma (Kidney Cancer)
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment and work by blocking protein interactions that normally prevent the immune system from recognizing and destroying cancer cells.
- Conditions
- Breast Cancer (Triple Negative Breast Cancer (TNBC)), Renal Cell Carcinoma (Kidney Cancer), Melanoma (Skin Cancer), Non-Small Cell Lung Cancer
- Trial name
- NCT07555210
- Testing
- Dual-Energy X-ray Absorptiometry (DXA), High Resolution peripheral Quantitative Computed Tomography (HRpQCT)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Jessica Mezzanotte Sharpe
Rectal Cancer
Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer
The purpose of this study is to find out what effects, good and/or bad, the combination of the study drug, capecitabine, and radiation have on you and your cancer.
- Trial name
- NCT01554969
- Testing
- capecitabine + ganetespib
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Emory University
MSS-type Low Rectal Cancer，Neoadjuvant Chemoradiotherapy, QL1706
Neoadjuvant Chemoradiotherapy Combined With QL1706 for MSS-Type Low-Rectal Cancer
he goal of this prospective, exploratory clinical trial is to learn if neoadjuvant chemoradiotherapy combined with QL1706 (a dual PD-1/CTLA-4 antibody) can effectively treat in patients with MSS-type low rectal cancer (tumor…
- Trial name
- NCT07866313
- Testing
- Neoadjuvant short-term radiotherapy and chemotherapy + iparomlimab and tuvonralimab, Neoadjuvant long-term radiotherapy and chemotherapy + iparomlimab and tuvonralimab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Changhai Hospital
Rectal Cancer
Advanced MR Imaging for Early Biologic Tumor Changes to Neoadjuvant Chemoradiation Treatment for Rectal Cancer
The purpose of this study is to see whether three new types of MRI techniques used during magnetic resonance imaging (MRI) of the pelvis to look at rectal cancer can help doctors to tell if the tumor is getting better in response…
- Trial name
- NCT01830582
- Testing
- Advanced MR Imaging
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Locally Advanced Rectal Cancer
The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSI-H Locally Advanced Rectal Cancer
The study evaluates the addition of immunotherapy of PD-1 antibody in neoadjuvant chemoradiotherapy in microsatellite stability-high (MSI-H) locally advanced rectal cancer (LARC).
- Trial name
- NCT04411524
- Testing
- PD-1 antibody, Capecitabine, Irinotecan
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fudan University
Cancer
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00049296
- Testing
- docetaxel, thalidomide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Case Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.